Skip to main content
OpenTrials

Clinical trial condition

Blood-Borne Infections

Explore clinical trials studying Blood-Borne Infections. Study availability and eligibility vary by location and protocol.

8,267 public trials 445 recruiting studies
Refine in advanced search Browse all conditions

Blood-Borne Infections trial results

Completed

Safety of and Immune Response to an HIV Preventive Vaccine (HIV-1 Gag DNA Alone or With IL-15 DNA) Given With or Without 2 Different Booster Vaccinations in HIV Uninfected Adults

NCT00115960

Conditions
Blood-Borne Infections, Communicable Diseases, Genital Diseases, +11 more
Locations
  • Brigham and Women's Hosp. CRS Boston, Massachusetts, United States
  • NY Blood Ctr./Union Square CRS New York, United States
  • HIV Prevention & Treatment CRS New York, United States
  • Univ. of Rochester HVTN CRS Rochester, New York, United States
View Trial Details
Completed

Safety of and Immune Response to a DNA HIV Vaccine Followed by an Adenoviral Vaccine Boost Given Three Different Ways to HIV Uninfected Adults

NCT00384787

Conditions
Blood-Borne Infections, Communicable Diseases, Genital Diseases, +11 more
Locations
  • Alabama Vaccine CRS Birmingham, Alabama, United States
  • Brigham and Women's Hospital Vaccine CRS (BWH VCRS) Boston, Massachusetts, United States
  • NY Blood Ctr./Union Square CRS New York, United States
  • Columbia P&S CRS New York, United States
View Trial Details
Completed

Safety and Immune Response Study of High-Dose Canarypox ALVAC-HIV Vaccine in Healthy, HIV Uninfected Adults

NCT00027261

Conditions
Blood-Borne Infections, Communicable Diseases, Genital Diseases, +12 more
Locations
  • Alabama Vaccine CRS Birmingham, Alabama, United States
  • San Francisco Vaccine and Prevention CRS San Francisco, California, United States
  • UCSF, Gen. Clinical Research Ctr., Mt. Zion Hosp. San Francisco, California, United States
  • Project Brave HIV Vaccine CRS Baltimore, Maryland, United States
View all 13 locations
View Trial Details
Completed

Safety of and Immune Response to an HIV-1 DNA Vaccine (VRC HIVDNA009-00-VP) in HIV Uninfected Adults

NCT00071851

Conditions
Blood-Borne Infections, Communicable Diseases, Genital Diseases, +11 more
Locations
  • Alabama Vaccine CRS Birmingham, Alabama, United States
  • San Francisco Vaccine and Prevention CRS San Francisco, California, United States
  • Project Brave HIV Vaccine CRS Baltimore, Maryland, United States
  • Johns Hopkins Bloomberg School of Public Health,Ctr for Immunization Research,Project SAVE-Baltimore Baltimore, Maryland, United States
View all 14 locations
View Trial Details
Completed

Safety of and Immune Response to Two HIV Vaccine Formulations (rMVA-HIV and rFPV-HIV) Alone or in Combination in HIV Uninfected Adults

NCT00083603

Conditions
Blood-Borne Infections, Communicable Diseases, Genital Diseases, +11 more
Locations
  • Alabama Vaccine CRS Birmingham, Alabama, United States
  • Saint Louis Univ. School of Medicine, HVTU St Louis, Missouri, United States
  • Univ. of Rochester HVTN CRS Rochester, New York, United States
  • FHCRC/UW Vaccine CRS Seattle, Washington, United States
View Trial Details
Completed

Safety of and Immune Response to an HIV Vaccine (VRC-HIVDNA009-00-VP) Administered With Interleukin-2/Immunoglobulin (IL-2/Ig) DNA Adjuvant in Uninfected Adults

NCT00069030

Conditions
Blood-Borne Infections, Communicable Diseases, Genital Diseases, +11 more
Locations
  • Project Brave HIV Vaccine CRS Baltimore, Maryland, United States
  • Brigham and Women's Hosp. CRS Boston, Massachusetts, United States
  • Fenway Community Health Clinical Research Site (FCHCRS) Boston, Massachusetts, United States
  • NY Blood Ctr./Union Square CRS New York, United States
View Trial Details
Completed

Safety of and Immune Response to an HIV-1 Vaccine Boost (VRC-HIVADV014-00-VP) in HIV Uninfected Adults Who Participated in HVTN 052

NCT00091416

Conditions
Blood-Borne Infections, Communicable Diseases, Genital Diseases, +11 more
Locations
  • Johns Hopkins Bloomberg School of Public Health,Ctr for Immunization Research,Project SAVE-Baltimore Baltimore, Maryland, United States
  • Fenway Community Health Clinical Research Site (FCHCRS) Boston, Massachusetts, United States
  • Saint Louis Univ. School of Medicine, HVTU St Louis, Missouri, United States
  • HIV Prevention & Treatment CRS New York, United States
View Trial Details
Completed

Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Uninfected Adults

NCT00054860

Conditions
Blood-Borne Infections, Communicable Diseases, Genital Diseases, +11 more
Locations
  • Brigham and Women's Hosp. CRS Boston, Massachusetts, United States
  • Fenway Community Health Clinical Research Site (FCHCRS) Boston, Massachusetts, United States
  • Saint Louis Univ. School of Medicine, HVTU St Louis, Missouri, United States
  • Miriam Hospital's HVTU Providence, Rhode Island, United States
View Trial Details

Related conditions